IR Department
  • About Us
    • Overview
    • Our Team
    • Our ESG Position
    • Careers
  • Services
    • What We Do
    • Investor Relations
    • IPO Readiness
    • Media Relations
    • Issues and Crisis Communications
    • Digital Content & Social Media Activation
    • Marketing and Brand Campaigns
    • Video Production
    • ESG
    • ESG Competent Boards Masterclass
  • News & events
    • Blog
  • Contact
    • Contact Us
    • Email Alerts
IR Department Newsletter - September 2022
News & events >
  • Blog

Recent Posts

  • HealthInvest April 2025 recap: bringing life sciences to the forefront
  • Upcoming: HealthInvest April 2025
  • Equity Insights: December Issue
  • Navigating AGM Season: Insights from Jane Lowe
  • 3 ways new ESG management and auditing standards could affect all Australian listed companies

Archives

  • April 2025
  • March 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • May 2024
  • December 2023
  • October 2023
  • July 2023
  • March 2023
  • February 2023
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • March 2022
  • February 2022

Categories

  • AGMs
  • Crisis communications
  • Equity Insights
  • ESG
  • Investor relations
  • Newsletter March 2022
  • Newsletter Sept 2022
  • Uncategorized

And That's a Wrap: HealthInvest 2024

Posted on September 24th, 2024 . Updated on September 27th, 2024 by Anna Cvijetić

We're still buzzing from the energy and excitement of our inaugural HealthInvest summit in partnership with Morgans and Stockhead, which took place on September 18 at Kittyhawk. This Sydney event exceeded expectations, featuring presentations from five leading and emerging life sciences companies and sparking valuable connections among investors, industry experts, and thought leaders.

Full House

HealthInvest definitely met our expectations, with a packed house of engaged attendees. Our presenting companies shared inspiring presentations, followed by some insightful Q&A, overseen by Morgan’s senior analyst, Scott Power. Our presenters included:

  • Imricor Medical Systems (ASX: IMR) - Nick Corkill, Vice President Corporate Strategy
  • Impedimed (ASX: IPD) - Dr Parmjot Bains, Managing Director & CEO
  • Race Oncology (ASX: RAC) - Dr Peter Smith, Executive Chair
  • Percheron Therapeutics (ASX: PER) - Dr James Garner, Managing Director & CEO
  • Clarity Pharmaceuticals (ASX: CU6) - Dr Alan Taylor, Executive Chair

The event offered a platform for investors to hear from five of the ASX’s most innovative life sciences companies, while also offering networking opportunities, sparking valuable connections and conversations.

Company Presentations

View a copy of the presentations here.

Media coverage and presenter videos

Our media partner, Stockhead released an event summary, accompanied by video interviews with each presenter. You can access the article to read and watch the content here.

See below for some highlights of the evening:

A Big Thank You!

We're grateful to our presenting companies for sharing their vision, to our partners, Morgans and Stockhead for their support and all our attendees for their enthusiasm and engagement. Until next time!

 

Posted in Uncategorized

IR Department acknowledge the Traditional Owners of the land on which it operates and pays respect to Elders past, present and emerging.

Subscribe

Which of the following group do you best fit?

 
By subscribing you agree to with our Privacy Policy

Site Map Privacy Search
IR Department . All rights reserved. - Site by